Targeted Therapies Could Make Rx Companies More Credible, Lilly Exec Says
Executive Summary
A move to more targeted therapies could improve trust of the pharmaceutical industry, Lilly New Product Planning Director Maureen Kiley told a Cambridge Healthtech Institute conference on targeted therapeutics
You may also be interested in...
Rituxan, Herceptin, Gleevec pricing (correction)
The wholesale acquisition cost of Genetech's Rituxan is $13,041 for a one-month course as monotherapy for relapsed/refractory, low grade or follicular, CD20+, B-cell non-Hodgkin's lymphoma and $19,561 for diffuse large CD20+ B-cell NHL (4.2 month average course of treatment); the firm's Herceptin has a WAC of $22,521 for metastatic breast cancer (7.2 month average course at $3,042 per month). According to data from Price Alert, the average wholesale price for Novartis' Gleevec ranges from approximately $3,348.27 to $5,022.36 per month for adults. "The Pink Sheet" reported a discussion of the pricing of the targeted oncologics that was based on inaccurate figures (1"The Pink Sheet" June 26, 2006, p. 22)...
Rituxan, Herceptin, Gleevec pricing (correction)
The wholesale acquisition cost of Genetech's Rituxan is $13,041 for a one-month course as monotherapy for relapsed/refractory, low grade or follicular, CD20+, B-cell non-Hodgkin's lymphoma and $19,561 for diffuse large CD20+ B-cell NHL (4.2 month average course of treatment); the firm's Herceptin has a WAC of $22,521 for metastatic breast cancer (7.2 month average course at $3,042 per month). According to data from Price Alert, the average wholesale price for Novartis' Gleevec ranges from approximately $3,348.27 to $5,022.36 per month for adults. "The Pink Sheet" reported a discussion of the pricing of the targeted oncologics that was based on inaccurate figures (1"The Pink Sheet" June 26, 2006, p. 22)...
FDA’s Rx/Dx Co-Development Approach Overlooks Incentives – Novartis Exec
FDA's concept paper on drug-diagnostic co-development does not account for "practical" issues facing firms, such as incentives, Novartis Oncology Diagnostic Development Director Mark Braganza said